Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes
- 368 Downloads
People with type 2 diabetes mellitus have an excess risk of macrovascular disease and a poorer prognosis. PROactive (PROspective pioglitAzone Clinical Trial In macro Vascular Events) was a landmark study of secondary cardiovascular disease (CVD) prevention in type 2 diabetes that suggested a beneficial effect of pioglitazone therapy on macrovascular outcomes. Previous studies have already shown that pioglitazone has a good safety and tolerability profile in people with type 2 diabetes, but PROactive provided an opportunity to assess tolerability and safety associated with long-term exposure in a vulnerable subpopulation at very high cardiovascular risk. This review discusses all the key safety and tolerability characteristics associated with pioglitazone therapy in PROactive.
As in previous studies, pioglitazone was associated with typical, but manageable, increases in oedema (26.4% vs 15.1% for placebo) and weight gain (mean change of +3.8 kg vs −0.6 kg for placebo). Increased hypoglycaemia with pioglitazone was consistent with improved glycaemic control. Despite more reports of serious heart failure in the pioglitazone group (5.7% vs 4.1% for placebo), there was a proportional improvement in macrovascular outcomes among patients developing heart failure, and absolute rates of macro-vascular events and mortality were similar to those in the placebo group. Liver function tests confirmed the hepatic safety of pioglitazone with long-term use and revealed a tendency to improved hepatic function, which may reflect reductions in liver fat. The comparative incidence of malignancies was similar; however, more cases of bladder neoplasm (14 vs 5) and fewer cases of breast cancer (3 vs 11) were observed in the pioglitazone versus placebo arms of the study. A higher rate of bone fractures observed among pioglitazone-treated female patients (5.1% vs 2.5%) warrants further investigation. Overall, safety and tolerability was predictable, and adverse events were not treatment limiting. These results suggest that any beneficial effects of pioglitazone on macrovascular outcomes are accompanied by good long-term tolerability in this population of very high-risk patients with type 2 diabetes and established CVD.
The authors would like to thank Absolute Healthcare Communications for editorial assistance. Funding for this assistance was provided by Takeda Pharmaceuticals.
PROactive was funded by Takeda Europe R&D Centre Ltd, London, UK, and Eli Lilly and Company, Indianapolis, IN, USA. The study was designed by the International Steering Committee, who approved the protocol and amendments. The commercial sponsor of PROactive had two representatives on the International Steering Committee and the same two were also members of the Executive Committee. Access to data was given freely to the Executive Committee and authors and the sponsors have not suppressed any data. Data interpretation, writing of this report and the decision to publish was made by all of the authors.
Professor Dormandy is a member of the Executive Committee. Drs Bhattacharya and van Troostenburg de Bruyn are employees of Takeda Global Research & Development.
- 4.National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 Dec; 106: 3143–421Google Scholar
- 8.Dormandy JA, Charbonnel B, Eckland DJ, et al., PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro-Vascular Events): a randomised controlled trial. Lancet 2005 Oct; 366: 1279–89PubMedCrossRefGoogle Scholar
- 10.Wilcox R, Kupfer S, Erdmann E, PROactive Study investigators. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J 2008 Apr; 155(4): 712–7PubMedCrossRefGoogle Scholar
- 11.Erdmann E, Dormandy JA, Charbonnel B, et al., PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. Results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49(17): 1772–80PubMedCrossRefGoogle Scholar
- 12.Wilcox R, Bousser MG, Betteridge DJ, et al., PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007 Sep; 38: 865–73PubMedCrossRefGoogle Scholar
- 13.Massi-Benedetti M, Scheen A, Charbonnel B. Pioglitazone delays the need for permanent insulin use: results from PROactive [abstract]. Diabetes 2006; 55: A124Google Scholar
- 14.Charbonnel B, Dormandy J, Erdmann E, et al., PROactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004 Jul; 27(7): 1647–53PubMedCrossRefGoogle Scholar
- 20.Scheen A, Charbonnel B. Reduced insulin requirements and improved glycemic control with pioglitazone in insulin-treated patients with type 2 diabetes: results from PROactive [abstract]. Diabetes 2006; 55 Suppl. 2: A134Google Scholar
- 40.Heine R, Schindhelm R, Diamant M. Long-term pioglitazone treatment improves markers of liver function: results from PROactive [abstract]. Diabetes 2006; 55 Suppl. 1: A115Google Scholar
- 50.Takeda Pharmaceutical Company Limited. Actos (pioglitazone hydrochloride) US package insert. Osaka: Takeda, 2004 AugGoogle Scholar
- 52.Charbonnel B, Birkeland K, Scheen A. Pioglitazone add-on to either metformin or sulfonylurea: glycaemic results from PROactive [abstract]. Diabet Med 2006; 23: 298Google Scholar
- 53.Charbonnel B, Scheen A. Pioglitazone in triple oral therapy: long-term glycemic results from PROactive [abstract]. Diabetes 2006; 55 Suppl. 2: A106Google Scholar
- 71.Spanheimer R, Perez A, Kupfer S, et al. Effects of pioglitazone versus glyburide on markers of liver safety: results from a 3-year, randomized, double-blind trial [abstract]. Diabetes 2006; 55 Suppl. 1: A75Google Scholar